Glaxosmithkline Pharmaceuticals Share Price Target 2025, 2026, 2030, 2040, 2050

GlaxoSmithKline Pharmaceuticals makes and sells medicines and vaccines, and is one of the top medicine companies in India. It works on diseases like infections, HIV, cancer, and immune system problems. It provides general medicines like painkillers, anti-infectives, skin medicines, and vitamins; vaccines for babies, teens, and adults for diseases like hepatitis, flu, chickenpox, and tetanus; and special medicines for breathing problems and HIV. The company has a factory in Nashik, works with other makers, and has a big network to deliver medicines all over India. Its goal is to help people stay healthy, feel better, and live longer.

What is Glaxosmi Pharma Ltd NSE: GLAXO?

GlaxoSmithKline Pharmaceuticals was established in 1924 in Mumbai, Maharashtra and is owned by the global GSK group. It is a big Indian medicine company that makes and sells many types of medicines and vaccines. These include common medicines, special medicines for breathing problems, HIV, and cancer, and vaccines for diseases like hepatitis, flu, chickenpox, and cervical cancer. Over time, the company has grown, added vaccines and cancer treatments, and is now one of India’s leading companies in making medicines and keeping people healthy.

Glaxosmi Pharma Share Price Target

Glaxosmi Pharma Share Price Target 2025

It is the Indian branch of the global company GSK plc. The company makes, develops, and sells medicines and vaccines all over India. Over the years, GSK India has become one of the most trusted medicine companies in the country. It is known for its high-quality products and focus on keeping people healthy. The company’s goal is not just to treat sickness, but also to prevent diseases, help people feel better, and live longer and healthier lives. In 2025, its share price target would be ₹3515, as per stock market analysts.

Its share price would be between ₹1921 to ₹3515 in 2025, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	1921	3515

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	1961	2272
February	1921	2744
March	2390	2988
April	2401	3148
May	2693	3398
June	3153	3515
July	3072	3450
August	2560	3184
September	2622	2883
October	2601	2795
November	2209	2974
December	2200	3087

Glaxosmi Pharma Share Price Target 2026

It works as a biopharma company under the bigger global GSK group. After separating its consumer healthcare business, it now focuses fully on prescription medicines, vaccines, and special treatments. The company combines research, making products, and distribution in one system, which helps it deliver medicines efficiently. This setup allows faster decisions, quicker innovation, and better response to India’s healthcare needs while following global standards and best practices. In 2026, its share price target would be ₹5017, as per stock market analysts.

Its share price would be between ₹2978 to ₹5017 in 2026, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2026	2978	5017

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	2978	3358
February	3125	3745
March	3521	3995
April	3668	4058
May	3712	4090
June	3898	4257
July	4025	4421
August	4210	4558
September	4310	4689
October	4385	4810
November	4621	4925
December	4721	5017

Share Price Target 2027

The company focuses on four main health areas: infectious diseases, HIV, cancer, and immune system problems. It also works on breathing problems and inflammation-related conditions. The company develop medicines and vaccines for both common sicknesses and serious diseases. It provides high-quality treatments and preventive care, making it a leader in regular medicines as well as advanced speciality treatments in India. In 2027, its share price target would be ₹6435, as per stock market analysts.

Its share price would be between ₹4889 to ₹6435 in 2027, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2027	4889	6435

Share Price Target 2028

It provides many general medicines for people of all ages. Its products include anti-infectives to fight infections, painkillers, skin medicines, and vitamins for overall health. These medicines help treat everyday sicknesses, keep people healthy, and boost immunity. Its medicines are of high quality and available widely. It helps millions of people get important treatments, supports hospitals and clinics, and improves public health across India. In 2028, its share price target would be ₹7733, as per stock market analysts.

Its share price would be between ₹6258 to ₹7733 in 2028, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2028	6258	7733

Share Price Target 2029

Vaccines are a very important part of the company. It provides vaccines for babies, children, teenagers, and adults to protect them from diseases like hepatitis, flu, chickenpox, and tetanus. Vaccines prevent serious illnesses and stop the spread of infections. It invests in research to make safe and effective vaccines for people in India. Through vaccines, the company supports health programs and makes preventive care available to communities all over the country. In 2029, its share price target would be ₹9007, as per stock market analysts.

Its share price would be between ₹7600 to ₹9007 in 2029, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2029	7600	9007

Glaxosmi Pharma share price Target 2030

The company invests in science, including research on the immune system, genetics, and new technologies. Its R&D focuses on infectious diseases, cancer, breathing problems, HIV, and immune system disorders. This helps the company create new medicines and vaccines that meet India’s health needs today and in the future. It stays at the front of medical innovation and gives patients access to advanced treatments. In 2030, its share price target would be ₹10560, as per stock market analysts.

Its share price would be between ₹8852 to ₹10560 in 2030, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2030	8852	10560

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	8852	9225
February	8910	9384
March	9000	9487
April	9087	9620
May	9325	9732
June	9515	9952
July	9741	10084
August	9790	10174
September	9857	10220
October	9980	10342
November	10020	10389
December	10151	10560

Share Price Target 2040

It has a strong distribution system that reaches all parts of India. It includes regional warehouses, local distributors, and sales centres to deliver medicines and vaccines quickly and reliably. This system helps doctors and hospitals in both cities and rural areas, so patients get the treatments they need. The company ensures its products are available widely, improving health and supporting India’s healthcare system. In 2040, its share price target would be ₹17524, as per stock market analysts.

Its share price would be between ₹15782 to ₹17524 in 2040, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2040	15782	17524

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	15782	16085
February	15890	16175
March	15921	16258
April	15978	16284
May	16020	16354
June	16121	16400
July	16221	16575
August	16284	16721
September	16358	16889
October	16412	16947
November	16584	17254
December	16847	17524

Share Price Target 2050

The company wants to expand its vaccines and special medicines to meet India’s changing health needs. It works to prevent diseases, improve patient care, and provide advanced treatments for serious and long-term conditions. Its goal is to make healthcare more effective and accessible, helping people stay healthier, feel better, and live longer while remaining a trusted partner in India’s healthcare system. In 2050, its share price target would be ₹23573, as per stock market analysts.

Its share price would be between ₹22105 to ₹23573 in 2050, as per stock market analysts.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2050	22105	23573

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	22105	22400
February	22187	22489
March	22220	22557
April	22284	22635
May	22354	22684
June	22412	22785
July	22510	22890
August	22574	23000
September	22625	23110
October	22841	23178
November	22910	23288
December	23080	23573

Should I buy Glaxosmi Pharma stock?

Year	Minimum Price (Rs)	Maximum Price (Rs)
2025	1921	3515
2026	2978	5017
2027	4889	6435
2028	6258	7733
2029	7600	9007
2030	8852	10560
2040	15782	17524
2050	22105	23573

It could be a safe choice if you want to invest for a few years. The company makes regular medicines, vaccines, and special treatments, and it has grown well recently. People always need its products, so the business is steady. Its strong points are a trusted name, regular sales, and chances to grow in new treatments. But there are some risks, like high stock prices, government rules, competition, and market ups and downs. It may not give quick profits, but it is good for steady long-term growth in healthcare.

Glaxosmi Pharma earnings results

	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales +	3,224	2,926	3,278	3,252	3,454	3,749	3,709
Expenses +	2,567	2,327	2,516	2,447	2,545	2,570	2,497
Operating Profit	657	598	762	804	909	1,179	1,212
OPM %	20%	20%	23%	25%	26%	31%	33%
Other Income +	-262	9	1,401	103	-21	149	156
Interest	6	4	2	2	2	1	2
Depreciation	83	79	68	66	70	67	66
Profit before tax	306	525	2,093	839	816	1,260	1,300
Tax %	70%	32%	19%	27%	28%	26%
Net Profit +	93	358	1,695	611	590	928	955
EPS in Rs	5.50	21.14	100.04	36.05	34.83	54.75	56.39
Dividend Payout %	727%	142%	90%	89%	92%	99%

Key Metrics

TTM PE Ratio	PB Ratio	Dividend Yield	Sector PE	Sector PB	Sector Div Yld
44.15	21.61	2.17%	37.17	5.87	0.58%

Peers & Comparison

Stock	PE Ratio	PB Ratio	Dividend Yield
GlaxoSmithKline Pharmaceuticals Ltd	45.46	21.61	2.17%
Sun Pharmaceutical Industries Ltd	39.62	5.97	0.89%
Torrent Pharmaceuticals Ltd	66.51	16.75	0.85%
Cipla Ltd	23.35	3.93	1.05%

Is Glaxosmi Pharma stock good to buy? (bull case & bear case)

Bull Case:

• This stock has a debt-to-equity ratio of around 0.02, showing very little debt.
• It has a Return on Capital Employed of around 57.7% meaning the company uses its capital efficiently to earn profits.
• It has a Return on Equity of around 56.5% indicating shareholders get good returns on their equity.
• This stock has an EPS of around ₹54.9 per share, showing that profit per share is healthy.
• It provides a dividend yield of around 2.15% offering some income to investors.
• This stock has a broad business mix including general medicines, vaccines and speciality treatments, which reduces risk from depending on a single product line.

Bear Case:

• This stock has a Price to Earnings ratio of around 44 to 45 times, meaning it is somewhat pricey given current earnings, and future growth is expected by the market.
• It provides a modest dividend yield of around 2.15% which may not be attractive for investors seeking high regular income.
• This stock’s growth depends on continuing performance and innovation, and if the company fails to deliver new products or execute well, it may affect returns.

Conclusion

It is a big medicine company in India. It makes regular medicines, vaccines, and special treatments for diseases like infections, HIV, cancer, and breathing problems. The company is strong and has little debt. It makes many different products, which makes it safer and more stable. Even though the stock price can be high and there are risks from competition and government rules, it is a good choice for steady long-term growth in healthcare.

FAQs